Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.94% |
| 2 | Consumer Discretionary | 14.99% |
| 3 | Communication Services | 11.27% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CSII
476
DELISTED
Cardiovascular Systems, Inc.
CSII
| $12.1M | 0.01% |
+353,017
| New | +$10.3M |
|
|
FCSC
477
DELISTED
Fibrocell Science Inc.
FCSC
| $11.9M | 0.01% |
196,199
+2,248
| +1% | +$131K |
|
478
Alaunos Therapeutics
TCRT
$4.59M
| $11.8M | 0.01% |
18,167
+12,944
| +248% | +$7.71M |
|
|
XOMA
479
DELISTED
Xoma
XOMA
| $11.6M | 0.01% |
+86,139
| New | +$8.68M |
|
480
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| $11.5M | 0.01% |
62,508
+28,208
| +82% | +$4.99M |
|
481
Douglas Emmett
DEI
$1.98B
| $11.5M | 0.01% |
494,469
-20,009
| -4% | -$477K |
|
482
MPLX
MPLX
$59.3B
| $10.8M | 0.01% |
242,686
+2,482
| +1% | +$94K |
|
|
KIN
483
DELISTED
Kindred Biosciences, Inc.
KIN
| $10M | 0.01% |
+901,774
| New | +$10.7M |
|
|
CMRX
484
DELISTED
Chimerix, Inc.
CMRX
| $9.94M | 0.01% |
657,558
+424,770
| +182% | +$6.78M |
|
|
TTPH
485
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $9.78M | 0.01% |
36,175
-9,899
| -21% | -$2.36M |
|
|
VIAB
486
DELISTED
Viacom Inc. Class B
VIAB
| $9.41M | 0.01% |
107,766
-60,318
| -36% | -$4.98M |
|
|
MKTO
487
DELISTED
MARKETO INC COM STK (DE)
MKTO
| $9.07M | 0.01% |
+244,586
| New | +$8.06M |
|
|
PKY
488
DELISTED
Parkway, Inc.
PKY
| $9M | 0.01% |
+466,560
| New | +$8.38M |
|
|
ATHL
489
DELISTED
ATHLON ENERGY INC COM
ATHL
| $8.95M | 0.01% |
295,818
+218
| +0.1% | +$6.92K |
|
|
PLG
490
Platinum Group Metals
PLG
$164M
| $8.75M | 0.01% |
74,749
| – | – |
|
|
EQM
491
DELISTED
EQM Midstream Partners, LP
EQM
| $8.58M | 0.01% |
145,880
+1,891
| +1% | +$100K |
|
|
NTLS
492
DELISTED
NTELOS HLDGS CORP COM
NTLS
| $7.89M | 0.01% |
389,793
-641,906
| -62% | -$12.8M |
|
493
Qualys
QLYS
$5.1B
| $7.42M | 0.01% |
+321,218
| New | +$7.14M |
|
494
Agios Pharmaceuticals
AGIO
$1.79B
| $7.36M | 0.01% |
307,235
+132,235
| +76% | +$3.01M |
|
|
YOKU
495
DELISTED
YOUKU TUDOU INC.(CAYMAN ISLS)
YOKU
| $7.3M | 0.01% |
240,797
+18,839
| +8% | +$541K |
|
|
PSXP
496
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $7.21M | 0.01% |
189,998
+2,229
| +1% | +$73.5K |
|
|
FURX
497
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
| $7.12M | 0.01% |
+169,407
| New | +$6.97M |
|
498
Corcept Therapeutics
CORT
$12.4B
| $6.91M | 0.01% |
2,144,742
+7,993
| +0.4% | +$16.2K |
|
|
ANAC
499
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $6.44M | 0.01% |
+383,700
| New | +$5.31M |
|
500
ExxonMobil
XOM
$644B
| $6.16M | 0.01% |
60,853
-1,570
| -3% | -$145K |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.